Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Radioimmunotherapy Rit Market size was valued at USD 3.3 billion in 2024 and is anticipated to surpass USD 21.7 billion by 2037, registering a CAGR of 17% during the forecast timeline i.e. 2025-2037. In 2025, the industry size of radioimmunotherapy rit is assessed at USD 3.8 billion.
The market is expanding significantly owing to the advances in antibody engineering, improvements in radiolabeling techniques, and a growing understanding of tumor biology that favors better patient selection for therapy. For instance, in March 2024, AstraZeneca completed the acquisition of Fusion Pharmaceuticals Inc. The acquisition was a major step toward AstraZeneca's mission to transform cancer treatment and patient outcomes by replacing traditional regimens such as chemotherapy and radiation with more targeted treatments. In addition, health care systems further prioritize personalized medicine approaches.
Furthermore, ongoing investments focus toward the development of next-generation radioimmunoconjugates. For instance, in June 2024, in a financing round headed by Amplitude Ventures, Ability Biologics announced the final closing at USD 18 million. The company's platform is dedicated to finding and creating effective and specific antibody treatments for immune-related diseases and cancer. Ability Biologics is producing new, logic-enabled antibodies that could be first-in-class or best-in-class treatments using its AbiLeapTM discovery engine. The market is poised to significantly contribute to better patient outcomes and standards of care within oncology.
Radioimmunotherapy Rit Sector: Growth Drivers and Challenges
Growth Drivers
- Rising incidences of cancer: One of the most significant growth drivers in the radioimmunotherapy rit market is the growing prevalence of cancer types such as hematological malignancies and solid tumors. This growth is largely attributed to increased prevalence cases due to lifestyle and demographic changes, thereby leading to an increased number of diagnoses for the disease. For instance, in February 2024, according to the IARC's 2022 report it is estimated that 35 million new cases of cancer will occur by 2050, primarily in countries with low and medium HDIs. The development of radioimmunotherapy is very promising in addressing this population of patients growingly expanding the healthcare provider's quest for the right treatment modalities.
- Advancement in monoclonal antibody technology: The major growth driver of the market is the improvement in monoclonal antibody technology, which improves the specificity and efficacy of targeted therapies. For instance, in June 2021, Kyowa Kirin Co. Ltd. and Amgen, Inc. signed a deal to develop and market KHK4083, a fully human monoclonal antibody used to treat atopic dermatitis. This collaboration has aided the company's growth. This technology enhances the efficacy of treatment and provides a solution to the escalating needs in oncology for personal approaches to medication, thereby repositioning radioimmunotherapy as an integral element of modern treatment strategies for cancer.
Challenges
- Limited patent eligibility: A major challenge to the market is the limited eligibility of patients, practically due to the specificity of tumor-associated antigens to which these treatments are targeted. Many patients may not express the required antigens on their cancer cells and, therefore, the applicability of such radioimmunotherapy to only a narrow subset of individuals. This drawback goes further than simply limiting treatment outcomes. Clinical decisions also become complex since health professionals must discern which of the patients is more likely to be helped through this novel technique and therefore discourage broader acceptance and utilization within oncology settings.
- Restricted clinical experience: This relative newness to the field constitutes another major challenge within the market since few practicing healthcare providers are conversant or have experience with the relatively new therapy. The inability to manage and administer it can result in variability in treatment protocols and patient care that may compromise therapeutic outcomes. This lack of sufficient clinical experience can further limit the use of radioimmunotherapy in daily oncology practices, thus limiting access for patients who might benefit from targeted therapy.
Radioimmunotherapy Rit Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
17% |
|
Base Year Market Size (2024) |
USD 3.3 billion |
|
Forecast Year Market Size (2037) |
USD 21.7 billion |
|
Regional Scope |
|
Radioimmunotherapy Rit Segmentation
Administration Route (Intravenous, Intrathecal, Intraperitoneal)
The intravenous segment is set to dominate over 65.9% radioimmunotherapy rit market share by 2037, mainly due to established efficacy and quick systemic distribution through intravenous. For instance, in July 2023, the National Library of Medicine unveiled that approximately 25 million people receive intravenous fluid therapy globally. Administered radioimmunotherapy via an intravenous infusion readily accesses the blood, effectively directly delivering the radio-labeled antibody to a tumor through efficiency in access that ensures effective and optimal bioavailability. This approach is more in harmony with the contemporary norms applied during oncological treatment and is liked more by clinicians when the treatment drug is administered to patients with all these types of cancers.
Radioisotope (Iodine-131, Yttrium-90, Lutetium-177, Thallium-201)
The iodine-131 segment is anticipated to dominate the radioimmunotherapy rit market throughout the projected timeframe because it is well-established regarding safety and shows significant efficacy for thyroid cancers and other particular types of hematologic malignancies. For instance, in July 2020, it is the phospholipid-drug conjugate (PDC) CLR 131.3 that delivers iodine-131 directly to the cytosol and cytoplasm of tumor cells. The possibility of CLR 131 in solid and hematologic tumors is being investigated by the biopharmaceutical company Cellectar Biosciences, located in Florham Park, New Jersey. This established track record not only enhances clinician confidence in its use but also reinforces iodine-131's position as a cornerstone in the development of radioimmunotherapy treatments.
Our in-depth analysis of the global market includes the following segments:
|
Administration Route |
|
|
Indication |
|
|
Target Antigen |
|
|
Radioisotope |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportRadioimmunotherapy Rit Industry - Regional Synopsis
North America Market Statistics
North America in radioimmunotherapy rit market is set to dominate over 45.9% revenue share by 2037. Since RIT targets specific cancers, it holds promise as a treatment for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and follicular lymphoma. Some of the key factors driving the market include rising healthcare costs, improvements in RIT technology, rising cancer rates, particularly in the region, and growing interest in personalized medicine.
In the U.S. market is likely to unveil lucrative growth opportunities during the projected timeframe attributable to the effective and supportive regulatory framework which eases the release and approval of novel drugs. For instance, in August 2024, Following the FDA's approval of Lupin's alliance partner, ForDoz Pharma Corporation, USA (ForDoz), Lupin Limited announced the launch of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials in the US.
Canada radioimmunotherapy rit market is exponentially increasing its footprints owing to the fundings and promoting of breakthroughs and innovative ideas from research institutions and pharmaceuticals companies. For instance, in September 2024, more than USD 31.4 million in provincial funding has been given to UBC researchers at Canada's Immuno-Engineering and Biomanufacturing Hub (CIEBH) for three projects. It will hasten the development of cutting-edge vaccines and treatments in British Columbia for all Canadians. This facility will allow researchers to create and manufacture clinical-grade treatments that satisfy Health Canada's exacting quality standards for use in clinical trials.
Asia Pacific Market Analysis
The radioimmunotherapy rit market in the Asia Pacific is likely to witness the fastest growth during the stipulated timeframe attributable to the precisely targeted cancer treatment that has been made possible by advancements in imaging technologies. Such as the introduction of positron emission tomography, or PET, and single-photon emission computed tomography, or SPECT. Notably, the global market for radioimmunotherapy will keep expanding due to advancements in technology, increased investment in the field, and evolving therapeutic techniques.
In India market is likely to witness robust growth owing to state-of-the-art innovations and research and development activities within the country. For instance, in November 2024, Dr. Reddy's Laboratories unveiled toripalimab, India's first immuno-oncology drug, to treat a rare kind of cancer. The drug can be used to treat nasopharyngeal carcinoma, a rare type of head and neck cancer. Toripalimab is advised as the first line of treatment for adults with metastatic or recurrent locally advanced NPC when paired with gemcitabine and cisplatin.
China radioimmunotherapy Rit market is likely to flourish at a fast pace during the stipulated timeline. The country is home to the world's largest workforce of cancer researchers, and they are making amazing progress in the fight against cancer. For instance, in November 2024, the researchers were interested in commentaries and thus explored fresh and provocative ideas through the pages of Cancer Discovery. This collection helped bridge the gaps between the Western and Eastern research communities and encourage fresh discussions and methods of investigation. Nine commentaries were chosen, and they addressed the non-H. pylori microbiome in gastric cancer, combining traditional Chinese medicine with Western medicine.
Companies Dominating the Radioimmunotherapy Rit Landscape
- Merck Co.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Roche
- Amgen
- Gilead Sciences
- Johnson Johnson
- Novartis
- Sanofi
- Astra Zeneca
- Bayer
- Pfizer
- BristolMyers Squibb
- AbbVie
- Eli Lilly and Company
The market is experiencing significant growth owing to the acquisitions and mergers between tech giants to foster innovative therapeutic treatment options. For instance, in May 2023, Freenome announced the acquisition of Oncimmune Ltd., with a CE-IVD-marked EarlyCDT Lung blood test. It is currently on the market, an autoantibody platform, and a research and development pipeline of over seven cancer detection patterns. Hence, such initiatives promote competitiveness and create a dynamic landscape in the market.
Here's the list of some key players:
In the News
- In May 2024, Blackstone announced the opening of Uniquity Bio with an emphasis on inflammation and immunology, as part of its Blackstone Life Sciences portfolio. With the FDA accepting Uniquity Bio's Phase 2 investigational new drug application for solrikitug, a monoclonal antibody that targets TSLP, and Blackstone providing up to USD 300 million in funding to expand the asset across several indications, the company is coming out of stealth.
- In May 2023, Aurigene Pharmaceutical Services intended to invest USD 40 million to construct a facility for producing therapeutic proteins, antibodies, and viral vectors. The facility was designed to help clients with small-scale production of antibodies and other recombinant proteins for preclinical and early phase clinical needs.
Author Credits: Radhika Pawar
- Report ID: 7093
- Published Date: Feb 05, 2025
- Report Format: PDF, PPT
